Skip to main content

Table 1 Parasite burden and genotyping results from archival cytological slides (Group A)

From: Microscopic and molecular analysis of Babesia canis in archived and diagnostic specimens reveal the impact of anti-parasitic treatment and postmortem changes on pathogen detection

Samples Tissuea Year of preparation Parasite burden PCR protocolsb
cytb 1 2 3
Postmortem samples
 A-1 Kidney 2003 286 (H) + + + +
 A-2 Kidney 2004 527 (VH) + +
 A-3 Spleen 2007 134 (M) + + + +
 A-4 Spleen 2008 4 (L) + + +
 A-5 Spleen 2009 97 (L) + + +
 A-6 Spleen 2010 32 (L) + +
 A-7a Kidney 2014 43 (L) + +
 A-7b Myocardium 2014 63 (L) + + + +
 A-8 Liver 2014 439 (VH) + + + +
Clinical samples
 A-9 CBS 2003 160 (M) + +
 A-10 CBS 2007 78 (L) + + + +
 A-11 CBS 2010 143 (M) + +
 A-12 CBS 2011 112 (M) + +
 A-13 CBS 2012 82 (L) +
  1. aTissue used for cytological slide preparation
  2. bProtocol 1: conventional Babesia/Theileria PCR using BAB1 and BAB2 primers for amplification of 560 bp 18S rRNA; Protocol 2: conventional Babesia/Theileria PCR after DNA concentration and purification using BAB1 and BAB2 primers for amplification of 560 bp 18S rRNA; Protocol 3, nested Babesia/Theileria PCR for amplification of 1750 bp 18S rRNA and 560 bp 18S rRNA in the first and second round, respectively
  3. Abbreviations: CBS, clinical blood smears made from the cephalic vein blood of clinical patients; L, low parasite burden; M, moderate parasite burden; H, high parasite burden; VH, very high parasite burden; cytb, mammalian cytochrome b